Profiles
The latest opinion pieces by industry thought leaders
-
Permission granted by BeiGene
A rising oncology powerhouse in China, BeiGene looks to strengthen its international punch
To expand its reach, Christiane Langer, the company’s head of medical affairs, is leaning on connections and singularity over fitting in a box.
Michael Gibney • March 14, 2023 -
Stock via Getty Images
The power of connections for a startup CEO
Priyanka Dutta-Passecker, head of wound-care specialist Healiva, discusses the importance of tapping her network in starting and running a biotech.
Alexandra Pecci • March 14, 2023 -
Peter Macdiarmid/Getty Images via Getty Images
Tapping into the molecular fountain of youth
Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.
Alexandra Pecci • Feb. 22, 2023 -
Stock via Getty Images
For Complement’s CEO, storytelling could be just as critical as data
Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.
Alexandra Pecci • Feb. 14, 2023 -
Permission granted by Biohaven
The unique playbook of Biohaven’s CEO
Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?
Meagan Parrish • Feb. 8, 2023 -
Permission granted by Alexion
United by inequity: The healthcare disparities plaguing rare disease patients and Black Americans
Guided by her personal experiences, Tamar Thompson is aiming to improve rare disease care through her advocacy work at Alexion, AstraZeneca Rare Disease.
Alexandra Pecci • Feb. 7, 2023 -
Permission granted by Ira Spector SFA Therapeutics
A biotech CEO’s favorite ‘F’ word
At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.
Taren Grom • Jan. 26, 2023 -
Enes Evren via Getty Images
Pro sports’ COVID protocols led to real-world data impacts for pharma
After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.
Karissa Waddick • Jan. 16, 2023 -
Stock via Getty Images
A new mission in menopause — extending the lives of women
Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.
Meagan Parrish • Jan. 5, 2023 -
Permission granted by Durect
Forks in the road lead one medical expert to a ‘game changing’ liver treatment
Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.
Alexandra Pecci • Jan. 3, 2023 -
Permission granted by CZI
How one of the world’s most prolific inventors is guiding a plan to tackle all disease
Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.
Alexandra Pecci • Dec. 15, 2022 -
Permission granted by Mahesh Karande
Chasing a ‘holy grail’ cancer gene
Omega Therapeutics’ president and CEO Mahesh Karande on its attempts to drug the elusive c-Myc gene.
Alexandra Pecci • Dec. 6, 2022 -
Permission granted by Evelina Vågesjö
How bacteria-enabled technology for wounds could also help cancer patients
Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.
Alexandra Pecci • Nov. 22, 2022 -
Permission granted by Sana Alajmovic
A ‘bold vision’ to prevent diabetes
Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts.
Alexandra Pecci • Nov. 15, 2022 -
Permission granted by Cresilon
This plant-based gel stops bleeding in seconds — and might have potential in drug delivery
29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.
Karissa Waddick • Nov. 9, 2022 -
Permission granted by Rami Elghandour
Chasing that ‘Time magazine cover potential’
Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.
Alexandra Pecci • Nov. 8, 2022 -
Permission granted by Tasuku Kitada
A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level
The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.
Alexandra Pecci • Oct. 25, 2022 -
Stock illustration via Getty Images
How a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development
Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.
Alexandra Pecci • Oct. 20, 2022 -
Permission granted by Amit Etkin
Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds
After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.
Alexandra Pecci • Oct. 11, 2022 -
Permission granted by Jim Lang
Red Jacket: Jim Lang
The CEO of Eversana has made his mark on the life sciences by disrupting the status quo for commercialization — and he’s got more industry-shifting changes in the works.
PharmaVoice staff • Sept. 15, 2022 -
Permission granted by Peyton Howell
Red Jacket: Peyton Howell
The chief operating and growth officer of Parexel has sold her market access company and created award-winning DE&I programs, but it’s her role as “connector” that she takes the greatest pride in.
PharmaVoice staff • Sept. 15, 2022 -
Permission granted by Quita Highsmith
Red Jacket: Quita Highsmith
The VP and chief diversity officer of Genentech is driving enterprise-wide strategies to influence how the biotech giant approaches DE&I — from clinical trials to career advancement.
PharmaVoice staff • Sept. 15, 2022 -
Permission granted by Fabio Gratton
Red Jacket: Fabio Gratton
The serial entrepreneur has relied on his gift for storytelling, creativity and a bit of “magic” as he’s launched one successful niche tech company after another.
PharmaVoice staff • Sept. 15, 2022 -
Permission granted by Udit Batra
Red Jacket: Udit Batra
A combination of logic and love — that’s how the CEO of Waters Corp. leads and how he inspires those around him to “solve the problems that matter.”
PharmaVoice staff • Sept. 15, 2022 -
Permission granted by Yvonne Greenstreet
Disrupters: Dr. Yvonne Greenstreet
The CEO of Alnylam — a leader in RNAi therapies — has the company at the top of its game scientifically and culturally.
PharmaVoice staff • Sept. 6, 2022
